Investor Presentaiton
sanofi
Nirsevimab expected to prevent 3x more RSV events than maternal vaccine
Modeled impact of nirsevimab and maternal immunization in a U.S. birth cohort for first RSV season
Key input
Prevented RSV-related Events:
Hospitalizations, Office and Emergency Room Visits
nirsevimab
Maternal Vaccine
[Modelled with clinical data & assumptions from CDC
comparison; not from head-to-head studies]
350,000
Efficacy RSV MA-LRTI
79.5%
51.3%
300,000
(success criteria not met)
Reduction of RSV MA-LRTI
hospitalization
83.2%
69.4%
250,000
% reduction of RSV-related events
in babies born before season
50.5%
12.7%
200,000
% reduction of RSV-related events
in babies born preterm
150,000
60.6%
4.1%
100,000
Immunization coverage rate
80%
50%
NEW
50,000
Efficacy all-cause LRTI
hospitalizations
58%
0
291,320
3х
90,173
2.5%¹
for MA-LRTI all-cause
(success criteria not met)
nirsevimab
RSV maternal PreF vaccine
Source Notes: Model- Kieffer A, Beuvelet M, Sardesai A, et al. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model. J Infect Dis. 2022;226(Supplement 2):S282-s292. Inputs:
Hospitalizations: CDC New Vaccine Surveillance Network (NVSN) hospitalization rates for children under 2 years of age from December 2016 to September 2020. Primary care & ER visits: Lively JY, Curns AT, Weinberg GA, et al. Respiratory Syncytial Virus-Associated Outpatient Visits
Among Children Younger Than 24 Months. J Pediatric Infect Dis Soc. 2019;8(3):284-286. RSV season: National Respiratory and Enteric Virus Surveillance System (NREVSS) (2015-2019). Immunization rates pediatric CDC National Center for Health Statistics, DTaP
https://www.cdc.gov/nchs/fastats/immunize.htm Immunization Rates Maternal: CDC FluVaxView Flu, Tdap, Covid Vaccination coverage among pregnant women April 2022 https://www.cdc.gov/flu/fluvaxview/pregnant-women-apr2022.htm. Efficacy nirsevimab: Simões EAF, Lancet Child
Adolesc Health. 2023 Mar;7(3):180-189. Drysdale S, 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (Lisbon). Griffin MP, et al. N Engl J Med. 2020;383(5):415-425. Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846. Beyfortus. EU Summary of Product
Characteristics (SmPC). Efficacy Maternal RSV preF vaccine: Kampmann B, Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med 2023;388:1451-64
1. Included RSV MA LRTI all cause (2.5%) in the absence of data for all cause LRTI hospitalization to compare
27
Vaccines Investor EventView entire presentation